Research
Antibody Discovery Hybridoma Platform
We use classic hybridoma technology to identify monoclonal antibodies. The platform includes the following four components.
Animal Immunization：Formulate the optimal immunization strategy according to different targets (immunogen, immunized animals, adjuvants, immunization methods, etc.).
Cell Fusion：The use of advanced electrofusion technology greatly improves the efficiency of cell fusion and provides guarantee for obtaining more high-quality hybridoma antibodies.
Antibody Screening：With high-throughput antibody screening equipment (ELISA, FACS), it escorts the efficient preparation of candidate antibodies.
Antibody Purification：Hybridoma antibody was produced in vitro and purified by affinity chromatography.
Bioengineering Platform
Antibody Engineering
Protein-Related Technologies are deployed specifically for research and development of therapeutic proteins. Therapeutic proteins-ｐrodrugs, ADC and antibodies–form the most important group of biotechnological agents in current use. Hongcheng owns and develops cutting-edge bio-engineering technologies as well as world-class manufacturing processes and facilities. At Hongcheng, we are working on the cutting-edge therapeutic antibodies focusing on antibody design,antibody discovery and antibody engineering.
Phage Display：
We have a complete phage display technology platform, including phage display library (such as naive and immune Library) and antibody engineering transformation based on phage display technology (such as FC engineering and FV Engineering).
Single Domain Antibody：
Based on Alpaca immune or naive library, single domain antibody is screened to construct multi-specific antibody.
Multi Antibody：
Design and screen bispecific or multi-specific antibody forms based on biological needs.
FV Transformation：
Based on structural design or phage display technology, carry out FV transformation project, including affinity maturity, stability transformation, condition dependent combination, etc.
FC Transformation：
Based on structural design or phage display technology, FC engineering includes enhancing or reducing effector function, improving FcRn binding, double specificity, etc.
RNA Science
mRNA representations a disruptive new drug class. In the past decade, mRNA has developed into a promising new class of drugs with great potential to meet various highly unmet medical needs. MRNA is a long chain molecule composed of four basic nucleotides according to genetic information, which can express bioactive protein molecules in cells.
Because of the high consistency of the physicochemical properties of mRNA, the development of mRNA therapy is very fast, whether for cancer, infectious diseases or rare diseases.
Our mRNA Technology：The structural elements of mRNA play a key role in its expression, including potential immunogenicity, translation efficiency and molecular stability. We have technical layout in the design, synthesis and production of mRNA.
Our mRNA Forms Include：Base modified mRNA, Replicable mRNA
Our mRNA Delivery Technologies Include：Lipid nanoparticles (LNPS): suitable for delivery of antibody mRNA, cytokine mRNA and rare disease replacement protein mRNA. Exosomes: suitable for preventing targeted and cell targeted delivery of mRNA.
Structural biology
Hongcheng has established a first-class Hongcheng Biopharma platform, which emphasizes both structure and function. Focusing on proteins and nucleic acids that are closely related to human diseases, it uses X-ray crystallography and three-dimensional reconstruction of frozen electron microscope to analyze their three-dimensional structures. At the same time, it uses functional experiments to clarify the relevant molecular mechanisms, so as to reveal the laws of disease occurrence and development, And then provide a reliable theoretical basis for clinical treatment and drug design. By analyzing the target and drug precise structure, we can help to find and design reasonable drug molecules, support the structure-activity relationship (SAR) and drug molecular optimization.
Pharmacology Platform
Preclinical pharmacy platform includes in vitro and in vivo pharmacology research and biomarker and diagnosis method development.
In Vitro Pharmacology：In vitro pharmacology can complete the in vitro pharmacodynamic research of tumor immunity, autoimmune diseases and ADC drug development. It mainly includes the study of T cell, macrophage, DC, B cell and cytokine function and the study of ADC in vitro efficacy, assisting in drug development and ind declaration.
In Vivo Pharmacology：In vivo pharmacology can complete the in vivo pharmacodynamic research of tumor immunity, autoimmune disease and ADC drug development, including a variety of CDX models, PDX models and autoimmune disease models, and assist in drug development and ind declaration.
Biomarker And Diagnosis：The development of biomarkers and diagnostic methods mainly includes the development of clinical research, the identification and development of biomarkers and the development of diagnostic methods for clinical research, and assisting the clinical research and development of tumor immunity, autoimmune diseases and ADC drugs.
Antibody Drug Conjugate (ADC) Platform
Efficacy and safety of ADC depends on the specific recognition of tumor antigens, antibodies with appropriate affinity and high endocytosis efficiency, linkers that cleave rapidly and effectively in tumor, and appropriate cytotoxins. The antibody coupled drug screening platform based on indirect labeling can quickly screen the appropriate combination of antibody and toxin. Screening antibodies suitable for ADC in the early stage of antibody discovery can effectively improve the efficiency and success rate of ADC research and development.
Antibody-Drug Conjugates：Traditional ADC is generated by first reduction of the antibody disulfide bonds followed by conjugation of linker with cytotoxin through cysteine coupling. Stability of the antibody decreases due to the reduction of disulfide bonds and it is difficult to ensure the uniformity of drug conjugation reflected by variations in the drug antibody ratio (DAR) values. These factors limit the efficacy of ADC and increase its toxicity. HONGCHENG adopts the patented glycosyl conjugation technology, which enables an uniform DAR and increases ADC stability resulting in stronger in vivo efficacy, lower in vivo toxicity, and a therapeutic toxicity window three times larger than traditional cysteine conjugation technology in general.
Next Generation Payload：Payloads (such as MMAE and DXD) have achieved success in many ADCs, but they are not satisfactory for some tumor targets. According to different indications and targets, HONGCHENG develops a variety of microtubule inhibitors, nucleic acid synthesis inhibitors and other toxins through internal research and external cooperation.
